COST-EFFECTIVENESS OF ETRANACOGENE DEZAPARVOVEC FOR THE TREATMENT OF HEMOPHILIA B

被引：0
|
作者：
Sarker, J. [1 ]
Moradi, A. [2 ]
Whittington, M. [2 ]
Tice, J. A. [3 ]
Herce-Hagiwara, B. [2 ]
Fahim, S. M. [2 ]
Chu, J. [3 ]
Agboola, F. O. [2 ]
Pearson, S. [2 ]
Rind, D. M. [2 ]
Walton, S. [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Inst Clin & Econ Review, Boston, MA USA
[3] UCST Sch Med, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE555
引用
收藏
页码：S160 / S161
页数：2
相关论文
共 50 条
  • [11] Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B
    Shah, Jinesh
    Kim, Hongseok
    Sivamurthy, Krupa
    Monahan, Paul E.
    Fries, Michael
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (02) : 227 - 237
  • [12] Recent progress in the development program of AMT-061 (etranacogene dezaparvovec) for persons with severe or moderately severe hemophilia B
    Pipe, Steven W.
    Miesbach, Wolfgang
    Von Drygalski, Annette
    Giermasz, Adam
    Meijer, Karina
    Coppens, Michiel
    Kampmann, Peter
    Klamroth, Robert
    Schutgens, Roger
    Key, Nigel S.
    Lattimore, Susan
    Recht, Michael
    Gomez, Esteban
    Castaman, Giancarlo
    Sawyer, Eileen K.
    Gut, Robert
    Leebeek, Frank W. G.
    HAEMOPHILIA, 2020, 26 : 21 - 21
  • [13] Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A
    Cook, Keziah
    Forbes, Shaun P.
    Adamski, Kelly
    Ma, Janice J.
    Chawla, Anita
    Garrison, Louis P., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 501 - 512
  • [14] Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
    Von Drygalski, Annette
    Giermasz, Adam
    Castaman, Giancarlo
    Key, Nigel S.
    Lattimore, Susan
    Leebeek, Frank W. G.
    Miesbach, Wolfgang
    Recht, Michael
    Long, Alison
    Gut, Robert
    Sawyer, Eileen K.
    Pipe, Steven W.
    BLOOD ADVANCES, 2019, 3 (21) : 3241 - 3247
  • [15] Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
    von Drygalski, Annette
    Gomez, Esteban
    Giermasz, Adam
    Castaman, Giancarlo
    Key, Nigel S.
    Lattimore, Susan U.
    Leebeek, Frank W. G.
    Miesbach, Wolfgang A.
    Recht, Michael
    Gut, Robert
    Dolmetsch, Ricardo
    Monahan, Paul E.
    Le Quellec, Sandra
    Pipe, Steven W.
    BLOOD ADVANCES, 2023, 7 (19) : 5671 - 5679
  • [16] MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B
    Gomez, E.
    Castaman, G.
    Key, N. S.
    Lattimore, S. U.
    Leebeek, F. W.
    Miesbach, W. A.
    Recht, M.
    von Drygalski, A.
    Cooper, D.
    Li, Y.
    Salazar, B.
    Pipe, S. W.
    HAEMOPHILIA, 2022, 28 : 74 - 75
  • [17] COST-EFFECTIVENESS OF EFMOROCTOCOG ALFA IN TREATMENT OF SEVERE HEMOPHILIA A PATIENTS IN TURKEY
    Tatar, M.
    Kamaci, E.
    Alhagiri, E.
    Alghamdi, M.
    VALUE IN HEALTH, 2023, 26 (12) : S102 - S102
  • [18] COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR SEVERE HEMOPHILIA A PATIENTS IN THE UNITED STATES
    Bolous, N.
    Chen, Y.
    Wang, H.
    Devidas, M.
    Bhakta, N.
    Reiss, U.
    VALUE IN HEALTH, 2022, 25 (07) : S366 - S366
  • [19] MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B
    Gomez, Esteban
    Giermasz, Adam
    Castaman, Giancarlo
    Key, Nigel S.
    Lattimore, Susan
    Leebeek, Frank W. G.
    Miesbach, Wolfgang A.
    Recht, Michael
    von Drygalski, Annette
    Cooper, David
    Li, Yanyan
    Salazar, Blanca
    Pipe, Steven W.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E41 - E42
  • [20] Gene therapy in hemophilia A: a cost-effectiveness analysis
    Machin, Nicoletta
    Ragni, Margaret V.
    Smith, Kenneth J.
    BLOOD ADVANCES, 2018, 2 (14) : 1792 - 1798
12345